Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
Advanced CancerPancreatic Cancer5 moreDetermine Phase 2 dose of study drug
Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal...
Metastatic Colorectal CancerThe objective is to compare the efficacy and safety of masitinib in combination with FOLFIRI ( irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients.
Trial of Adoptive T Cell Therapy With Activated P53 Specific T Cells for Treatment of Advanced Colorectal...
Colorectal CarcinomaThe study "Phase I trial of Adoptive T cell Therapy with Activated P53 specific T cells for Treatment of Advanced Colorectal Cancer" is an open label, single arm trial.
Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line...
Metastatic Colorectal CancerThe purpose of this study is to assess whether a structured physical activity program (PA) during palliative chemotherapy improves progression-free survival (PFS) and/or patient-reported outcomes (ESAS-r) in patients with metastatic colorectal cancer.
Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal...
MSIColoRectal Cancer3 moreThe primary objective of this study is to determine the anti-tumor activity, as measured by overall response rate (ORR) of atezolizumab in combination with bevacizumab in patients with chemotherapy resistant CRC and positivity for MSI-like molecular signature. This is an international, open-label single arm (non-randomized), one-stage phase II trial.
Special Combination of BBI608 and Pembrolizumab
Metastatic Colorectal Cancerthe efficacy and safety of BBI608 in combination with pembrolizumab
Regorafenib + Panitumumab for Colorectal Cancers
KRAS and NRAS Wild-type Colorectal CancerEvaluate the safety of regorafenib and panitumumab
HIPEC and Systemic Chemotherapy in Unresectable Peritoneal Metastases From Colorectal Cancer
Peritoneal Metastases From Colorectal CancerThe prognosis of patients with unresectable peritoneal metastases from colorectal cancer is poor. These patients may obtain survival benefit from radical colorectal resection and cytoreductive surgery (CRS). The response rates of previous conversion therapy are low. Hyperthermic intraperitoneal chemoperfusion (HIPEC) and systemic chemotherapy are effective methods of reducing peritoneal cancer index (PCI) levels. The purpose of this study is to investigate the efficacy and safety of HIPEC and systemic chemotherapy in the conversion therapy of peritoneal metastases from colorectal cancer.
Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study...
Advanced Malignant NeoplasmAdvanced Melanoma52 moreThis trial studies the genetic analysis of blood and tissue samples from patients with cancer that has spread to other anatomic sites (advanced) or is no longer responding to treatment. Studying these samples in the laboratory may help doctors to learn how genes affect cancer and how they affect a person's response to treatment.
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations...
Colorectal CancerA phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with metastatic colorectal cancer (mCRC) that became refractory to first- and second-line standard therapies. Eligible patients will be assigned to one of several treatment arms.